Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)
Status:
Completed
Trial end date:
2014-08-15
Target enrollment:
Participant gender:
Summary
This open label, single-arm, non-controlled, multicentre study will determine the effect of
ambrisentan on exercise capacity (6MWT) in Chinese subjects with PAH. The study consists of a
screening period of 4 weeks, a 12-week primary evaluation period (PEP) and a 12-week
dose-adjustment period (DAP). Ambrisentan 5 mg will be administered to eligible subjects for
12 weeks (PEP).